对 ThyroSeq 结果中的不确定甲状腺病变进行风险分层：临床病理学与细胞学结果相关性的单一机构经验

IF 2.6 3区医学 Q3 ONCOLOGY

Cancer Cytopathology Pub Date : 2024-09-19 DOI:10.1002/cncy.22905

Wen-Yu Hsiao, Nabil F. Saba, Daniel Lubin, Amy Chen, Qiuying Shi

引用次数: 0

摘要

ThyroSeq提供了对不确定甲状腺结节，尤其是那些被归类为意义未定的不典型结节（AUS）进行恶性风险分层（ROM）的机会。然而，ThyroSeq的解释是否与细胞学特征、管理和手术结果相关仍不清楚。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single-institution experience of clinicopathologic correlation with cytologic findings

ThyroSeq offers the opportunity to stratify the risk of malignancy (ROM) in the characterization of indeterminate thyroid nodules, especially those categorized as atypia of undetermined significance (AUS). However, whether ThyroSeq interpretations correlate with cytologic features, management, and surgical outcome remains unclear.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cytopathology 医学-病理学

CiteScore

7.00

自引率

17.60%

发文量

130

审稿时长

1 months

期刊介绍： Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.